Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead product candidate, MOLBREEVI, is an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company aims to provide improved treatment options for individuals affected by these conditions.
- Website
- savarapharma.com
- Issuer profile
- All listings